NCT06975150View on ClinicalTrials.gov

Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

August 30, 2028

Study Completion Date

August 30, 2028

Conditions

Primary Sclerosing Cholangitis (PSC)

Interventions

DRUG

HK-660S 100mg

Administered orally

DRUG

HK-660S 200mg

Administered orally

DRUG

Placebo

Administered orally

Sponsors

Lead Sponsor

CuromeBiosciences

All Listed Sponsors

lead

CuromeBiosciences

INDUSTRY

NCT06975150 - Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter